2834 – Page 120 – China Stock Advice

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-K: (Original Filing)

[TABLE OFNTENTS TO ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED DECEMBER 31, 2011 Page PART I Item 1. Business 2 Item 1A. Risk Factors 10 Item 1B. Unresolved Staffmments 16 Item 2. Properties 16 Item 3. Legal Proceedings 18 PART II Item 5. 20 Item 7. Managements Discussion and Analysis of Financialnditions and Results] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1.I have reviewed this annual report on Form 10-K ofystar Bio-Pharmaceuticalmpany; 2.Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this annual report on Form 10-K ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer March 30, 2012] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. Bing Mei Chief Financial Officer March 30, 2012]

By info| 2016-02-05T03:21:08+00:00 March 30th, 2012|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 10-K, 2012-03-30, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-K: (Original Filing)

[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, Inc. as of December 31, 2011 Subsidiary Place of incorporation Shaanxi Biostar BioTech Ltd. People’s Republic of China Variable interest entities Place of incorporation Shaanxi Aoxing Pharmaceutical Co., Ltd, People’s Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, LLC People’s Republic of China EX-21 2 ex21.htm] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated March 27, 2012 relating to the consolidated financial statements of Biostar Pharmaceuticals, Inc. as of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. (No. 333-161598) We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 EX-23.2 4 ex23-2.htm] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 8 ex32-2.htm]

By info| 2016-03-03T12:11:13+00:00 March 27th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 10-K, 2012-03-27, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-K: FORM 10-K (Mark One) x December 31, 2011

[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, Inc. as of December 31, 2011 Subsidiary Place of incorporation Shaanxi Biostar BioTech Ltd. People’s Republic of China Variable interest entities Place of incorporation Shaanxi Aoxing Pharmaceutical Co., Ltd, People’s Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, LLC People’s Republic of China EX-21 2 ex21.htm] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated March 27, 2012 relating to the consolidated financial statements of Biostar Pharmaceuticals, Inc. as of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. (No. 333-161598) We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 EX-23.2 4 ex23-2.htm] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 8 ex32-2.htm]

By info| 2016-03-03T12:12:52+00:00 March 27th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-K, 2012-03-27, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-K: FORM 10-K (Mark One) x December 31, 2011

[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, of December 31, 2011 Subsidiary Place oforporation Shaanxi Biostar BioTech Peoples Republic of China Variable interest entities Place oforporation Shaanxi Aoxing Pharmaceutical Peoples Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, Peoples Republic of China] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to yourorporation of our audit reportted March 27, 2012 relating to thensolidated financial statements of Biostar Pharmaceuticals, of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form 10-K of] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, (No. 333-161598) We herebynsent to theorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 ex23-2.htm 4 EX-23.2] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 7 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 8 EX-32.2]

By info| 2016-02-07T15:55:09+00:00 March 27th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-K, 2012-03-27, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

TPI [TIANYIN PHARMACEUTICAL] POS AM: (Original Filing)

[Registration No. 333-163563 Post Effective Amendment No.1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang Chief Executive Officer] [HUNTER TAUBMAN WEISS LLP 17 State Street, Suite 2000 New York, New York 10007 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com March 27, 2012 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: In so acting, we have examined and relied upon the originals or] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 1 to a Registration Statement on Form S-1 pertaining to the registration of 15,784,640 shares of]

By info| 2016-03-27T19:36:20+00:00 March 27th, 2012|Categories: Chinese Stocks, SEC Original, TPI|Tags: 0001362718, 2012-03-27, 2834, PHARMACEUTICAL PREPARATIONS, POS_AM, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] POS AM: Registration No. 333-163563 Post Effective Amendment No.1 to

[Registration No. 333-163563 Post Effective Amendment No.1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang Chief Executive Officer] [HUNTER TAUBMAN WEISS LLP 17 State Street, Suite 2000 New York, New York 10007 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com March 27, 2012 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: In so acting, we have examined and relied upon the originals or] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 1 to a Registration Statement on Form S-1 pertaining to the registration of 15,784,640 shares of]

By info| 2016-03-27T19:37:29+00:00 March 27th, 2012|Categories: Chinese Stocks, TPI, Webplus ver|Tags: 0001362718, 2012-03-27, 2834, PHARMACEUTICAL PREPARATIONS, POS_AM, TPI|0 Comments

CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[FORM 10-K x For the fiscal year ended December 31, 2011 or ¨ For the transition period from _________ to _____________ 001-34471 China Pharma Holdings, Inc. Delaware 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Common Stock, par value $0.001 per] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-164049 on Form S-3 and Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 14, 2012 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries appearing in this] [CERTIFICATION (Section 302 of the Sarbanes-Oxley Act of 2002) I, Zhilin Li, certify that: 1. I have reviewed this Annual Report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [CERTIFICATION (Section 302 of the Sarbanes-Oxley Act of 2002) I, Frank Waung, certify that: 1. 2. 3. 4. a. b. c. d. 5. a. b.] [CERTIFICATION (Section 906 of the Sarbanes-Oxley Act of 2002) (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. s/ Zhilin Li / Zhilin Li EX-32.1 8 cphi10kex321123111.htm] [CERTIFICATION (Section 906 of the Sarbanes-Oxley Act of 2002) (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Frank Waung Chief Financial Officer (principal financial officer and principal accounting officer) EX-32.2 9 cphi10kex322123111.htm]

By info| 2016-03-03T17:50:51+00:00 March 14th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 10-K, 2012-03-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] 10-K: FORM 10-K x For the fiscal year ended

[FORM 10-K x For the fiscal year ended December 31, 2011 or ¨ For the transition period from _________ to _____________ 001-34471 China Pharma Holdings, Inc. Delaware 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Common Stock, par value $0.001 per] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-164049 on Form S-3 and Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 14, 2012 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries appearing in this] [CERTIFICATION (Section 302 of the Sarbanes-Oxley Act of 2002) I, Zhilin Li, certify that: 1. I have reviewed this Annual Report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [CERTIFICATION (Section 302 of the Sarbanes-Oxley Act of 2002) I, Frank Waung, certify that: 1. 2. 3. 4. a. b. c. d. 5. a. b.] [CERTIFICATION (Section 906 of the Sarbanes-Oxley Act of 2002) (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. s/ Zhilin Li / Zhilin Li EX-32.1 8 cphi10kex321123111.htm] [CERTIFICATION (Section 906 of the Sarbanes-Oxley Act of 2002) (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Frank Waung Chief Financial Officer (principal financial officer and principal accounting officer) EX-32.2 9 cphi10kex322123111.htm]

By info| 2016-03-03T17:53:49+00:00 March 14th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 10-K, 2012-03-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] 10-K: FORM 10-K x For the fiscal year ended

[FORM 10-K x For the fiscal year ended December 31, 2011 or For the transition period from _________ to _____________ 001-34471 China Pharmas, Delaware 73-1564807 (State or other jurisdiction oforporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Wensent to theorporation by reference in Registration Statement No. 333-164049 on Form S-3 and Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our reportted March 14, 2012 relating to thensolidated financial statements of China Pharmas, and subsidiaries appearing in this Annual] [CERTIFICATION (Section 302 of therbanes-Oxley Act of 2002) I, Zhilin Li, certify that: 1. I have reviewed this Annual Report on Form 10-K of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [CERTIFICATION (Section 302 of therbanes-Oxley Act of 2002) I, Frank Waung, certify that: 1. 2. 3. 4. a. b. c. d. 5. a. b. Frank Waung Chief Financial Officer (principal financial officer and principal accountingofficer) cphi10kex312123111.htm 7 EX-31.2] [CERTIFICATION (Section 906 of therbanes-Oxley Act of 2002) (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. s/ Zhilin Li / Zhilin Li cphi10kex321123111.htm 8 EX-32.1] [CERTIFICATION (Section 906 of therbanes-Oxley Act of 2002) (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany. Frank Waung Chief Financial Officer (principal financial officer and principal accounting officer) cphi10kex322123111.htm 9 EX-32.2]

By info| 2016-02-07T22:05:19+00:00 March 14th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 10-K, 2012-03-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)

[WuXi PharmaTech (Cayman) Inc. Form 6-K TABLE OF CONTENTS Page 3 4]

By info| 2016-04-02T17:46:16+00:00 March 12th, 2012|Categories: Chinese Stocks, SEC Original, WX|Tags: 0001403132, 2012-03-12, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, WX|0 Comments